NCT06419712

Effect of Vitamin D Supplementation on Glutathione Peroxidase (GPx) Activity, Interleukin-6 (IL-6) Levels and Clinical Outcomes in Post-COVID-19 Patients

Name: Clinical Trial NCT06419712
Creator: Escuela Militar de Graduados de Sanidad, SEDENA
Keywords: Post-COVID19 Condition, vitamin D (cholecalciferol) supplementation, drug, clinical trial, Mexico

Escuela Militar de Graduados de Sanidad, SEDENA·ClinicalTrials.gov·drugCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Post-COVID19 Condition
Drug/Device/Intervention: vitamin D (cholecalciferol) supplementation
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Escuela Militar de Graduados de Sanidad, SEDENA
Location: Mexico City, Mexico

Timeline & enrollment

Phase: N/A
Start date: Nov 25, 2022
End date: May 25, 2023
Enrollment: 54 participants

Primary outcome

Glutathione Peroxidase (GPx) Activity,Neuropsychiatric Symptoms (Anxiety and Depression)

Summary

The goal of this clinical trial is to evaluate the effectiveness of vitamin D supplementation in treating neuropsychiatric symptoms and improving antioxidant levels in individuals diagnosed with post-COVID-19 condition, a state known as long-COVID. These individuals are primarily adults who have recovered from severe COVID-19 and exhibit persistent symptoms. The main questions it aims to answer are:  Does vitamin D (cholecalciferol) supplementation decrease levels of anxiety and depression in patients with post-COVID-19 condition? Does vitamin D (cholecalciferol) supplementation increase glutathione peroxidase (GPx) activity in these patients? Researchers will compare the effects of daily versus bolus doses of vitamin D (cholecalciferol) to see if one method is more effective than the other in achieving sufficient vitamin D levels and improving clinical outcomes.  Participants will:  Be randomly assigned to receive either a daily dose or a bolus dose of vitamin D over an 8-week period.  Undergo blood tests to measure biochemical markers such as interleukin-6 (IL-6) and GPx before and two months after starting supplementation.  Have their lung function tested using spirometry and diffusing capacity for carbon monoxide.  Complete the Hospital Anxiety and Depression Scale to assess changes in anxiety and depression levels.

ICD-10 classifications

COVID-19, virus identifiedCOVID-19, virus not identifiedHIV disease resulting in other specified conditionsObservation for suspected disease or condition, unspecifiedAmenorrhoea, unspecified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06419712
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06419712 through Pure Global AI's free database. This phase not specified trial is sponsored by Escuela Militar de Graduados de Sanidad, SEDENA and is currently Completed. The study focuses on Post-COVID19 Condition. Target enrollment is 54 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.